Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562872 · ClinicalTrials.gov registry record · Phase 1
DSM265 Prophylaxis of Plasmodium Falciparum Malaria
A Phase 1 study of Healthy, sponsored by Medicines for Malaria Venture.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02562872: Completed Phase 1 study of Healthy, sponsored by Medicines for Malaria Venture.
NCT02562872 is a Phase 1 study of Healthy that has completed, run by Medicines for Malaria Venture. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02562872, a Phase 1 study of Healthy, has completed, sponsored by Medicines for Malaria Venture.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265 including up to two cohorts of healthy male and female volunteers aged 18 to 45 years. The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DSM265
- BIOLOGICAL Sporozoites
- BIOLOGICAL Infective mosquito bite
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center - Prevention Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02562872
The ClinicalTrials.gov registry entry for NCT02562872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Medicines for Malaria Venture, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02562872 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT02562872 about?
NCT02562872 is a clinical study titled "DSM265 Prophylaxis of Plasmodium Falciparum Malaria". The study is a single centre, randomised, placebo-controlled, double-blind study with DSM265 including up to two cohorts of healthy male and female volunteers aged 18 to 45 years. The study will be conducted into two sequential parts (Cohort 1 and Cohorts 2a and 2b).
What is the current status of trial NCT02562872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-03. Estimated completion is 2017-05.
What conditions does trial NCT02562872 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02562872?
The interventions under investigation include: Placebo (DRUG), DSM265 (DRUG), Sporozoites (BIOLOGICAL), Infective mosquito bite (BIOLOGICAL).
Who is sponsoring clinical trial NCT02562872?
This trial is sponsored by Medicines for Malaria Venture, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02562872 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.